Using the cancer risk management model to evaluate colorectal cancer screening options for Canada

Current Oncology

Volumn 22, Issue 2, 2015, Pages e41-e50

  Coldman, Andrew James ^a   Phillips, N ^a   Brisson, J ^b   Flanagan, W ^c   Wolfson, M ^d   Nadeau, C ^c   Fitzgerald, N ^e   Miller, A B ^f  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b Institut National de Santé Publique   (Canada)

^c STATISTICS CANADA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Canadian Partnership Against Cancer   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Colorectal cancer; Costs; Outcomes; Screening

Indexed keywords

ARTICLE; CANADA; CANCER RISK; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; DISEASE SIMULATION; FECES ANALYSIS; FOLLOW UP; HUMAN; IMMUNOCHEMISTRY; INFORMATION PROCESSING; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; RISK MANAGEMENT; SIGMOIDOSCOPY;

EID: 84928251783     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2013     Document Type: Article

References (67)

1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society; 2013.
2. World Health Organization (who). Cancer Fact Sheet No. 297 [Web page]. Geneva, Switzerland: who; 2014. [Current version available at: http://www.who.int/mediacentre/factsheets/fs297/en/; cited November 18, 2013]
3. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365–71.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–71.
5. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472–7.
6. Atkin WS, Edwards R, Kralj-Hans I, et al. on behalf of the UK Flexible Sigmoidoscopy Trial. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624–33.
7. Schoen RE, Pinsky PF, Weissfeld JL, et al. on behalf of the plco project team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345–57.
8. Segnan N, Armaroli P, Bonelli L, et al. on behalf of the score working group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial—score. J Natl Cancer Inst 2011;103:1310–22.
9. Evans WK, Wolfson MC, Flanagan WM, et al. Canadian Cancer Risk Management Model: evaluation of cancer control. Int J Technol Assess Health Care 2013;29:131–9.
10. Canadian Partnership Against Cancer (cpac). Home > Quality and planning > Professionals > System planning > Cancer risk management model [Web page]. Toronto, ON; cpac; 2011. [Available at: http://www.cancerview.ca/cv/portal/Home/QualityAndPlanning/QPProfessionals/SystemPlanning/CancerRiskManagementModel; cited October 1, 2013]
11. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma– carcinoma sequence. Br J Surg 2002;89:845–60.
12. Maroun J, Ng E, Berthelot J, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can 2003;24:91–101.
13. Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med 2007;26:98–109.
14. Eide TJ, Stalsberg H. Polyps of the large intestine in Northern Norway. Cancer 1978;42:2839–48.
15. Sieg A, Theilmeier A. Results of colonoscopy screening in 2005: an Internet based documentation [German]. Disch Med Wochenschr 2006;131:379–383.
16. Hofstad B. Colon polyps: prevalence rates, incidence rates, and growth rates. In: Waye JD, Rex DK, Williams CB, eds. Colonoscopy: Principles and Practice. Hoboken, NJ: Wiley– Blackwell; 2003: 358–76.
17. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal cancer screening for detection of advanced neoplasia. N Engl J Med 2006;355:1863–72.
18. Gerharz CD, Gabbert H, Krummel F. Age-dependent shift-tothe- right in the localization of colorectal adenomas. Virchows Arch A Pathol Anat Histopathol 1987;411:591–8.
19. Vatn MH, Stalsbert H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982;49:819–25.
20. Nusko G, Mansmann U, Altendorf-Hofmann A, Groitl H, Wittenkind C, Hanhn EG. Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis 1997;12:267–71.
21. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23:835–42.
22. Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol 1986;21:853–62.
23. Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 2007;56:1585–9.
24. O’Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study: patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990;98:371–9.
25. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci), Cancer Intervention and Surveillance Modeling Network. Colorectal Cancer Model Profiles [Web resource]. Bethesda, MD: nci; 2013. [Available at: http://cisnet.cancer.gov/colorectal/profiles.html; cited November 25, 2013]
26. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659–69.
27. Telford J, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. CMAJ 2010;182:1307–13.
28. Heitman SJ, Hilsden R, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010;7:e1000370.
29. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci). Simulation Models for Colorectal Cancer [Web resource]. Bethesda, MD: nci; 2010. [Available at: http://cisnet.cancer.gov/projections/colorectal/simulation.php#overview; cited August 30, 2013]
30. Levin TR. Natural history of colorectal adenomas and cancer. In: Pignone M, Russell L, Wagner J, eds. on behalf of the Institute of Medicine and National Research Council. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press; 2005.
31. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343–50.
32. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Nat Cancer Inst 2010;102:89–95.
33. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1–8.
34. Habr-Gama A, Waye JD. Complications and hazards of gastrointestinal endoscopy. World J Surg 1989;13:193–201.
35. Lohsiriwat V. Colonoscopic perforation: incidence, risk factors, management and outcome. World J Gastroenterol 2010;16:425–30.
36. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638–58.
37. Lüning TH, Keemers-Gels MH, Berendregt WB, Tan AC, Rosman C. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc 2007;21:994–7.
38. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103–10.
39. Rozen P, Comaneshter D, Levi Z, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010;116:2115–25.
40. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017–25.
41. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259–65.
42. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82–90.
43. Graser A, Stieber P, Nagel D, et al. Comparison of ct colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58:241–8.
44. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462–70.
45. Rabeneck L, Rumble RB, Thompson F, et al. Fecal i mmunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131–47.
46. Terhaar sive Droste JS, Oort FA, van der Hulst RW, et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2011;20:272–80.
47. Wilschut JA, Habbema DF, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011;103:1741–51.
48. Rex DK. Screening for colorectal cancer using colonoscopy. In: Anderson JC, Kahi CJ, eds. Colorectal Cancer Screening. New York, NY: Springer; 2011: 67–79.
49. Mapp TJ, Hardcastle JD, Moss SM, Robinson MH. Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening. Br J Surg 1999;86:1286–91.
50. Ontario Ministry of Health and Long-Term Care (mohltc). Schedule of Benefits for Physician Services under the Health Insurance Act. Toronto, ON: mohltc; 2013.
51. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Ann Surg 1998;228:59–63.
52. Roth LS, Adams PC. Variation in physician reimbursement for endoscopy across Canada. Can J Gastroenterol 2009;23:503–5.
53. Huang J, Zhou S, Groome P, Tyldesley S, Zhang-Solomans J, Mackillop WJ. Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol 2001;19:137–44.
54. Hollander MJ, Tessaro A. Health Care Use at the End of Life in Saskatchewan. Ottawa, ON: Canadian Institute for Health Information; 2008. [Available online at: http://www.health.gov.sk.ca/end-of-life-report; cited October 1, 2013]
55. Ontario Ministry of Health and Long-Term Care (mohltc), Health Data Branch. Ontario Case Costing Guide. Toronto, ON: mohltc; 2010.
56. Heresbach D, Manfredi S, D’halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006;18:427–33.
57. Hoff G, Grotmol T, Skovlund E, Bretthauer M on behalf of the Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846.
58. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (plco) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst 2012;104:280–9.
59. Dinh T, Ladabum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol 2013;11:1158–66.
60. Jeong KE, Cairns JA. Review of economic evidence in the prevention and early detection of colorectal cancer. Health Econ Rev 2013;3:20.
61. Phillips N, Coldman AJ. Computer simulation of the effect of different colorectal cancer screening strategies for British Columbia. B C Med J 2003;45:254–8.
62. Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK. Canada’s Population Health Model (pohem): a tool for performing economic evaluations of cancer control interventions. Eur J Cancer 2001;37:1797–804.
63. Bordt M, Cameron GJ, Gribble SF, Murphy BB, Rowe GT, Woolfson MC. The Social Policy Simulation Database and Model: an integrated tool for tax/transfer policy analysis. Can Tax J 1990;38:48–65.
64. Huserau D, Drummond M, Petrou S, et al. on behalf of the ispor Health Economic Evaluation Publication Guidelines–cheers Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (cheers)—explanation and elaboration: a report of the ispor Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231–50.
65. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290–308.
66. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013;62:409–15.
67. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697–706.